ConductScience.org, home

Paper41364346

Overview of ocular toxicities associated with breast cancer therapies.

Greenberg MR and 2 others. Breast Cancer Res Treat, 2025. Cited by 2 papers, by iCite.

Cite this record

ConductScience Library. Overview of ocular toxicities associated with breast cancer therapies. Papers, record 41364346. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41364346

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Overview of ocular toxicities associated with breast cancer therapies.
PubMed
Journal
Breast Cancer Res Treat
PubMed
Year
2025
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
2
iCite
Revised in PubMed
2026-01-07
PubMed

Authors3

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Greenberg MRMegan R
2Noveihed AAlexandra
3George MMridula

Source PubMed

Download CSV of authors

Topics6

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Breast NeoplasmsMajor topic
Eye DiseasesMajor topic
Antineoplastic AgentsMajor topic
Humans
Female
Molecular Targeted Therapy

References66

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
136084384Current and future burden of breast cancer: Global statistics for 2020 and 2040.Breast2022https://conductscience.org/library/papers/36084384PubMed
215850816Sex hormone receptors in the human eye.Surv Ophthalmol2005https://conductscience.org/library/papers/15850816PubMed
340377437Influence of tamoxifen on ocular morphology and function.Oncologist2025https://conductscience.org/library/papers/40377437PubMed
431479143Medication Use for the Risk Reduction of Primary Breast Cancer in Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.JAMA2019https://conductscience.org/library/papers/31479143PubMed
536495379Relationship between tamoxifen and cataracts: a nationwide cohort study of women in South Korea.Breast Cancer Res Treat2023https://conductscience.org/library/papers/36495379PubMed
67929848Tamoxifen blocks chloride channels. A possible mechanism for cataract formation.J Clin Invest1994https://conductscience.org/library/papers/7929848PubMed
79747868Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.J Natl Cancer Inst1998https://conductscience.org/library/papers/9747868PubMed
831813590Prevalence and Risk Factors of Tamoxifen Retinopathy.Ophthalmology2020https://conductscience.org/library/papers/31813590PubMed
936781026Tamoxifen retinopathy.Surv Ophthalmol2023https://conductscience.org/library/papers/36781026PubMed
1034956737Update on Retinal Drug Toxicities.Curr Ophthalmol Rep2021https://conductscience.org/library/papers/34956737PubMed
1130973440TAMOXIFEN-INDUCED CHORIORETINAL CHANGES: An Optical Coherence Tomography and Optical Coherence Tomography Angiography Study.Retina2020https://conductscience.org/library/papers/30973440PubMed
1235246390Ocular Toxicity in Breast Cancer Management: Manual for The Oncologist.Clin Breast Cancer2022https://conductscience.org/library/papers/35246390PubMed
1334972698Ocular Side Effects of Aromatase Inhibitor Endocrine Therapy in Breast Cancer - A Review.In Vivo2022https://conductscience.org/library/papers/34972698PubMed
1425597370Electroretinographic and optical coherence tomography findings in breast cancer patients using aromatase inhibitors.Cutan Ocul Toxicol2016https://conductscience.org/library/papers/25597370PubMed
1537931898Risk of ocular adverse events with aromatase inhibitors.Can J Ophthalmol2024https://conductscience.org/library/papers/37931898PubMed
1621819259Breast cancer medications and vision: effects of treatments for early-stage disease.Curr Eye Res2011https://conductscience.org/library/papers/21819259PubMed
1720470238Exemestane-induced corneal epithelial changes.Cutan Ocul Toxicol2010https://conductscience.org/library/papers/20470238PubMed
1834646621Review of the Literature on Ocular Complications Associated With Aromatase Inhibitor Use.Cureus2021https://conductscience.org/library/papers/34646621PubMed
1928680952A Review of Fulvestrant in Breast Cancer.Oncol Ther2017https://conductscience.org/library/papers/28680952PubMed
2035584336
Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial.
J Clin Oncol2022https://conductscience.org/library/papers/35584336PubMed

See all 66 referencesDownload CSV of references

Cited by1

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 2 citations.

PMIDTitleJournalYearIn Papers
41898248Ocular Toxicities of Anticancer Therapies in the Era of Precision Oncology: A Practical, Clinically Oriented Narrative Review.Biomedicines2026https://conductscience.org/library/papers/41898248

Source PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41364346

GET https://conductscience.org/api/papers/v1/41364346/references?page=2